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Abstract
Objective To evaluate two commercial stool tests for
detection of secretory IgA antibodies against gliadin
and human tissue transglutaminase for diagnosis of
coeliac disease in children with symptoms.
Setting Tertiary care children’s hospital.
Participants Coded stool samples from 20 children
with newly diagnosed coeliac disease and 64 controls.
Six children with coeliac disease had stool tests every
two weeks for three months after starting a gluten-free
diet.
Main outcome measures Secretory IgA antibodies
against gliadin and human tissue transglutaminase in
stool samples, determined in duplicate by using
recommended cut-off limits.
Results Sensitivity of faecal antibodies against human
tissue transglutaminase was 10% (95% confidence
interval 1% to 32%), and specificity was 98% (91% to
100%). For antibodies against gliadin, sensitivity was
6% (0% to 29%) and specificity was 97% (89% to
100%). Optimisation of cut-off limits by receiver
operating characteristic analysis and use of results of
both tests increased sensitivity to 82%, but specificity
decreased to 58%. All follow-up stool tests remained
negative, except for two positive anti-gliadin results in
one patient, six and 10 weeks after the gluten-free diet
was started.
Conclusions Neither stool test was suitable for
screening for coeliac disease in children with
symptoms.
Introduction
Serological screening for antibodies against gliadin,
endomysium, or tissue transglutaminase before the
diagnostic biopsy is done is well established practice in
patients with suspected coeliac disease. These anti-
bodies can be detected in faecal supernatants,1 and
commercial stool tests have been developed and
offered by many laboratories. However, no validation
data on these tests have been published. We evaluated
two stool tests (Immundiagnostik GmbH, Bensheim,
Germany) in comparison with serological results and
duodenal histology as “gold standard” in children who
had had upper endoscopy for different abdominal
conditions.
Methods
The study cohort consisted of 20 children with newly
diagnosed coeliac disease (median age 5.4 (range
0.9-14.1) years), all with duodenal villous atrophy
(Marsh III)2 plus positive endomysium antibodies in
serum, and 64 control children (5.6 (0.9-17.5) years)
with normal histology (Marsh 0) and negative
endomysium antibodies (61/61 tested). We excluded
patients with selective IgA deficiency, previously
diagnosed coeliac disease, or bloody diarrhoea.
We analysed coded stool samples for secretory IgA
antibodies against recombinant human tissue trans-
glutaminase in all 20 children with coeliac disease and
62/64 children without coeliac disease. We analysed
samples for antibodies against gliadin in 17/20
children with coeliac disease and 61/64 controls.
Results
Faecal tissue transglutaminase antibodies were positive
in two children with coeliac disease and two children
without coeliac disease (sensitivity 10%, 95% confi-
dence interval 1% to 32%; specificity 98%, 91% to
100%). Faecal anti-gliadin antibodies were positive in
one child with coeliac disease and one control patient
(sensitivity 6%, 0% to 29%; specificity 97%, 89% to
100%). Six patients with coeliac disease provided stool
samples before and every two weeks for three months
after starting a gluten-free diet, which all remained
negative, except for two positive anti-gliadin test results
in one patient, six and 10 weeks after starting the
gluten-free diet.
The  values between histology and stool test were
0.093 ( − 0.033 to 0.219) for tissue transglutaminase
antibodies and 0.062 ( − 0.027 to 0.151) for anti-gliadin
antibodies, indicating no agreement. The figure gives
the individual titres in relation to age. When we
optimised cut-off limits by receiver operating charac-
teristic analysis and combined both tests, sensitivity
increased to 82% but specificity decreased to 58%, with
positive and negative predictive values of 37% and
92%. These figures may change when the tests are used
prospectively on new cases. The prevalence of coeliac
disease in our cohort was 29% (17/59), but in the gen-
eral population, with an assumed prevalence of 0.5%,
the positive predictive value would decrease to 1%, with
marginal improvement of the negative predictive value
compared with the pre-test situation (from 99.5% to
99.8%).
Discussion
Both stool tests were negative in most cases of coeliac
disease and hence are not reliable as screening tests.
We have validated these stool tests against the accepted
diagnostic “gold standard” for coeliac disease. In many
European countries, validation of a diagnostic test in
the target population is not required before commer-
cialisation, or diagnostic tests are marketed for years
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without any evaluation. Many paediatric gastroenter-
ologists share our experience of receiving referrals
with a request to do endoscopy on the basis of a posi-
tive stool test result. Even worse, children have been
started on a gluten-free diet on the basis of positive
stool test results alone.
The tests in our study measure secretory IgA
antibodies, in contrast to specific IgA antibodies used
in a previous investigation in adults with coeliac
disease.1 Attempts to measure specific secretory IgA in
saliva and small intestinal aspirates found them to be
less sensitive than determination of antibodies in
serum.3 Another explanation for the poor sensitivity
could be the digestion of antibodies along the bowel
passage. We conclude that laboratory tests for clinical
purposes need to be evaluated before their release for
routine use. We propose that only adequately validated
diagnostic tests should be reimbursed by health insur-
ance.
Contributors: MK designed the study, did statistical analysis, and
wrote the manuscript with SK. SK-E helped with the study
design and supervised the test procedures in the laboratories.
VD helped HZ to do the stool tests, collected clinical data from
CRF, helped with the statistical analysis, and recruited the
coeliac patients for the follow-up part of the study. HZ did the
stool tests. SK is the study coordinator and guarantor, designed
the study protocol, and wrote the final manuscript with MK.
Funding: Immundiagnostik, Bensheim, Germany provided test
kits for antibody determinations in stool samples. Otherwise, the
company gave no financial support for the study, except for
reimbursement of travel costs to MK, who reported the results at
two scientific meetings. Immundiagnostik was not involved in
the study design, the collection and interpretation of data, the
writing of the report, or the decision to submit the paper for
publication.
Competing interests: MK has been reimbursed by Immundiag-
nostik, the manufacturer of the test system, for attending two
conferences. All other authors: none declared.
Ethical approval: The ethical committee of the Ludwig Maximil-
ians University approved the use of anonymised frozen stool
and serum samples for the purpose of this study.
1 Picarelli A, Sabbatella L, Di TM, Di CT, Vetrano S, Anania MC.
Antiendomysial antibody detection in fecal supernatants: in vivo proof
that small bowel mucosa is the site of antiendomysial antibody
production. Am J Gastroenterol 2002;97:95-8.
2 Marsh MN. Gluten, major histocompatibility complex, and the small
intestine: a molecular and immunobiologic approach to the spectrum of
gluten sensitivity (‘celiac sprue’). Gastroenterology 1992;102:330-54.
3 Patinen P, Bjorksten F, Malmstrom M, Savilahti E, Reunala T. Salivary and
serum IgA antigliadin antibodies in dermatitis herpetiformis. Eur J Oral
Sci 1995;103:280-4.
(Accepted 8 November 2005)
doi 10.1136/bmj.38688.654028.AE
U/
l
0
10
100
A
1
Non-coeliac disease
Coeliac disease
Age (years)
U/
l
0 2 4 6 8 10 12 14 16 18
0
10
100
Cut-off
Cut-off
B
1
Results of individual stool samples: (A) secretory IgA antibodies
against gliadin from 17 patients with coeliac disease and 61 control
children with gastrointestinal diseases other than coeliac disease but
normal duodenal histology; (B) secretory IgA antibodies against
human tissue transglutaminase from 20 patients with coeliac disease
and 62 controls. Marked cut-off value of 100 U/l suggested by
manufacturer. Values <1 U/l plotted as 1 U/l
What is already known on this topic
New commercial stool tests are promoted for
non-invasive screening of patients suspected of
having coeliac disease, but these tests have not
been validated
What this study adds
Determination of faecal IgA antibodies against
gliadin and human tissue transglutaminase failed
to detect symptomatic coeliac disease in children
One hundred years ago
Colour blindness on the football field
When George Wilson of Edinburgh gave an account of the
mistakes made by colour-blind persons, including medical
students who were unable to distinguish the colour of certain
precipitates, of engine-drivers, and of sailors who mistook signal
lights or flags, of tailors who matched red with green, and
bookbinders who did the same for coloured leathers and papers,
and when Jeffries in America added to an already long list the
mistakes made by colour-blind Government officials who sold
postage stamps, to neither of them does it seem to have occurred
that this question touched the great realm of sport. The Referees
Committee of the Lancashire Football Association have decided
in consequence of numerous complaints that certain referees are
shortsighted or colour blind, that prior to next season all referees
on the junior list shall come up for examination, in order that
their acuity of vision and their colour sense may be properly
tested. (BMJ 1906;i:262)
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